Simand Pierre-François, Berthod Grégoire, Parmentier Laurent, Anchisi Sandro
Service d'oncologie, HUG, 1211 Genève 14.
Service d'oncologie, Centre hospitalier du Valais romand, Hôpital du Valais, Avenue du Grand-Champsec 86, 1950 Sion.
Rev Med Suisse. 2020 May 27;16(695):1086-1091.
Dermatologic toxicities appear to be the most prevalent immunotherapy related adverse effects, both with anti-PD-1 and anti-CTLA-4 agents, as well as with the newly developed anti-PD-L1. They occur in more than one-third of the patients treated with immune check point inhibitors, regardless of the cancer being treated. They mainly manifest in the form of self-limiting maculopapular rashes and pruritus. Early recognition and management are essential in order to mitigate the severity of the lesions. A multidisciplinary team is crucial for optimal management.
